Updates are available Addendum dated 2023-04-24
Click to view Addendum: https://doi.org/10.1038/s41596-023-00838-3
-
Authors
Zaw Thin, May http://orcid.org/0000-0003-0036-2776
Moore, Christopher
Snoeks, Thomas
Kalber, Tammy
Downward, Julian http://orcid.org/0000-0002-2331-4729
Behrens, Axel http://orcid.org/0000-0002-1557-1143
- License Information
-
More Information
Article History
Received: 19 April 2021
Accepted: 9 August 2022
First Online: 9 December 2022
Competing interests
: J.D. has acted as a consultant for AstraZeneca, Jubilant, Theras, BridgeBio and Vividion, and has funded research agreements with BMS and Revolution Medicines. None of the other authors of this manuscript has a financial interest related to this work.
